This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

macrophage activation syndrome (MAS)

Authoring team

Macrophage Activation Syndrome (also known as Hemophagocytic lymphohistiocytosis (HLH)

  • when associated with rheumatic disorders, is a frequently fatal complication of infections, rheumatic disorders, and hematopoietic malignancies
    • often termed a “cytokine storm,” MAS occurs among the rheumatic diseases most typically in Still's disease but also in systemic lupus erythematosus and Kawasaki disease (2)
    • can also accompany infection, malignancy, and inborn errors of immunity (2)
  • is a life-threatening condition that is usually diagnosed among febrile hospitalized patients (children and adults) who commonly present with unremitting fever and a shock-like multiorgan dysfunction scenario
  • laboratory studies reveal:
    • pancytopenia
    • elevated liver enzymes
    • elevated markers of inflammation (ESR, CRP)
    • hyperferritinemia,
    • features of coagulopathy
  • in about 60% of cases, excess hemophagocytosis (macrophages/histiocytes engulfing other hematopoietic cell types) is noted on biopsy specimens from the bone marrow, liver, lymph nodes, and other organs (1)

Reference:

  1. Eloseily EM, Cron RQ. Macrophage Activation Syndrome. The Microbiome in Rheumatic Diseases and Infection. 2018 Mar 13:151–82.
  2. Nigrovic, PA. Macrophage Activation Syndrome. Arthritis Rheumatol 2025; 77: 367-379

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.